Literature DB >> 21628593

Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells.

Kristi Baker1, Shuo-Wang Qiao, Timothy T Kuo, Victoria G Aveson, Barbara Platzer, Jan-Terje Andersen, Inger Sandlie, Zhangguo Chen, Colin de Haar, Wayne I Lencer, Edda Fiebiger, Richard S Blumberg.   

Abstract

Cross-presentation of IgG-containing immune complexes (ICs) is an important means by which dendritic cells (DCs) activate CD8(+) T cells, yet it proceeds by an incompletely understood mechanism. We show that monocyte-derived CD8(-)CD11b(+) DCs require the neonatal Fc receptor for IgG (FcRn) to conduct cross-presentation of IgG ICs. Consequently, in the absence of FcRn, Fcγ receptor (FcγR)-mediated antigen uptake fails to initiate cross-presentation. FcRn is shown to regulate the intracellular sorting of IgG ICs to the proper destination for such cross-presentation to occur. We demonstrate that FcRn traps antigen and protects it from degradation within an acidic loading compartment in association with the rapid recruitment of key components of the phagosome-to-cytosol cross-presentation machinery. This unique mechanism thus enables cross-presentation to evolve from an atypically acidic loading compartment. FcRn-driven cross-presentation is further shown to control cross-priming of CD8(+) T-cell responses in vivo such that during chronic inflammation, FcRn deficiency results in inadequate induction of CD8(+) T cells. These studies thus demonstrate that cross-presentation in CD8(-)CD11b(+) DCs requires a two-step mechanism that involves FcγR-mediated internalization and FcRn-directed intracellular sorting of IgG ICs. Given the centrality of FcRn in controlling cross-presentation, these studies lay the foundation for a unique means to therapeutically manipulate CD8(+) T-cell responses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21628593      PMCID: PMC3116387          DOI: 10.1073/pnas.1019037108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

Review 1.  Cross-priming in health and disease.

Authors:  Christian Kurts; Bruce W S Robinson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

Review 2.  Fc-receptors as regulators of immunity.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Adv Immunol       Date:  2007       Impact factor: 3.543

Review 3.  Intracellular mechanisms of antigen cross presentation in dendritic cells.

Authors:  Sebastian Amigorena; Ariel Savina
Journal:  Curr Opin Immunol       Date:  2010-02-18       Impact factor: 7.486

Review 4.  Proteases in MHC class I presentation and cross-presentation.

Authors:  Kenneth L Rock; Diego J Farfán-Arribas; Lianjun Shen
Journal:  J Immunol       Date:  2010-01-01       Impact factor: 5.422

5.  Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens.

Authors:  Sarah L Jongbloed; Andrew J Kassianos; Kylie J McDonald; Georgina J Clark; Xinsheng Ju; Catherine E Angel; Chun-Jen J Chen; P Rod Dunbar; Robert B Wadley; Varinder Jeet; Annelie J E Vulink; Derek N J Hart; Kristen J Radford
Journal:  J Exp Med       Date:  2010-05-17       Impact factor: 14.307

6.  Monocyte-derived dendritic cells exhibit increased levels of lysosomal proteolysis as compared to other human dendritic cell populations.

Authors:  Nathanael McCurley; Ira Mellman
Journal:  PLoS One       Date:  2010-08-02       Impact factor: 3.240

7.  Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas.

Authors:  Cheolho Cheong; Ines Matos; Jae-Hoon Choi; Durga Bhavani Dandamudi; Elina Shrestha; M Paula Longhi; Kate L Jeffrey; Robert M Anthony; Courtney Kluger; Godwin Nchinda; Hyein Koh; Anthony Rodriguez; Juliana Idoyaga; Maggi Pack; Klara Velinzon; Chae Gyu Park; Ralph M Steinman
Journal:  Cell       Date:  2010-10-29       Impact factor: 41.582

8.  Toll-like receptor 5-deficient mice have dysregulated intestinal gene expression and nonspecific resistance to Salmonella-induced typhoid-like disease.

Authors:  Matam Vijay-Kumar; Jesse D Aitken; Amrita Kumar; Andrew S Neish; Satoshi Uematsu; Shizuo Akira; Andrew T Gewirtz
Journal:  Infect Immun       Date:  2008-01-14       Impact factor: 3.441

9.  Podocytes use FcRn to clear IgG from the glomerular basement membrane.

Authors:  Shreeram Akilesh; Tobias B Huber; Hui Wu; Gary Wang; Björn Hartleben; Jeffrey B Kopp; Jeffrey H Miner; Derry C Roopenian; Emil R Unanue; Andrey S Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-15       Impact factor: 11.205

10.  Different cross-presentation pathways in steady-state and inflammatory dendritic cells.

Authors:  Elodie Segura; Anthony L Albiston; Ian P Wicks; Siew Yeen Chai; José A Villadangos
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-16       Impact factor: 11.205

View more
  100 in total

Review 1.  Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies.

Authors:  Imre Kacskovics; Judit Cervenak; Anna Erdei; Richard A Goldsby; John E Butler
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

Review 2.  The specialized roles of immature and mature dendritic cells in antigen cross-presentation.

Authors:  Richard A Hopkins; John E Connolly
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

3.  Monoclonal antibodies directed against human FcRn and their applications.

Authors:  Gregory J Christianson; Victor Z Sun; Shreeram Akilesh; Emanuele Pesavento; Gabriele Proetzel; Derry C Roopenian
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

Review 4.  Mucosal antibodies in the regulation of tolerance and allergy to foods.

Authors:  M Cecilia Berin
Journal:  Semin Immunopathol       Date:  2012-07-10       Impact factor: 9.623

5.  Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis.

Authors:  Jiang-Jiang Qin; Wei Wang; Sushanta Sarkar; Ruiwen Zhang
Journal:  J Control Release       Date:  2016-07-06       Impact factor: 9.776

Review 6.  FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin.

Authors:  Michal Pyzik; Timo Rath; Wayne I Lencer; Kristi Baker; Richard S Blumberg
Journal:  J Immunol       Date:  2015-05-15       Impact factor: 5.422

7.  Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery.

Authors:  Eric M Pridgen; Frank Alexis; Timothy T Kuo; Etgar Levy-Nissenbaum; Rohit Karnik; Richard S Blumberg; Robert Langer; Omid C Farokhzad
Journal:  Sci Transl Med       Date:  2013-11-27       Impact factor: 17.956

Review 8.  Targeting FcRn for the modulation of antibody dynamics.

Authors:  E Sally Ward; Siva Charan Devanaboyina; Raimund J Ober
Journal:  Mol Immunol       Date:  2015-03-09       Impact factor: 4.407

Review 9.  Targeting FcRn to Generate Antibody-Based Therapeutics.

Authors:  E Sally Ward; Raimund J Ober
Journal:  Trends Pharmacol Sci       Date:  2018-08-22       Impact factor: 14.819

Review 10.  Cross-presentation of IgG-containing immune complexes.

Authors:  Kristi Baker; Timo Rath; Wayne I Lencer; Edda Fiebiger; Richard S Blumberg
Journal:  Cell Mol Life Sci       Date:  2012-07-31       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.